Ordu Merkez

Researchers are evaluating which of three common root-canal rinsing methods best reduces bacteria in adults needing root-canal treatment. The study focuses on whether chitosan alone, sodium hypochlorite combined with chitosan, or sodium hypochlorite combined with EDTA achieves the greatest bacterial reduction inside the root canal. This randomized controlled trial aims to provide clearer information on effective irrigation solutions for dental infections like apical periodontitis and root canal infection. Participants are randomly assigned to one of three groups chitosan irrigation only sodium hypochlorite followed by chitosan or sodium hypochlorite followed by EDTA. Each solution is delivered into the root canal with specific contact times and followed by a sterile saline flush. Treatment takes place over two clinic visits the first involves standard root-canal therapy with sample collection before and after rinsing, and the second visit, about a week later, is for a check-up and final tooth filling. Participants will provide tiny samples from inside the root canal for bacterial measurement before and immediately after treatment. They will also record any pain or discomfort for three days post-treatment using a diary or phone calls. The main outcome measured is the change in bacterial load inside the canal from before to after treatment. The study lasts about one week, involves approximately 90 adults, and all procedures are routine dental care provided at no cost. Participants may withdraw at any time and can ask questions throughout the trial.

Researchers are evaluating a family-centered comfort intervention for children aged 5 to 10 years who are hospitalized in a pediatric intensive care unit PICU. This randomized controlled trial aims to determine if adding this intervention to routine nursing care can improve child comfort, reduce anxiety and fear, and enhance sleep, while also decreasing parental anxiety and increasing satisfaction with care. Children in the intervention group will receive a comfort approach that includes listening to their mothers voice through storytelling, dimmed environmental lighting, and the use of a weighted blanket alongside standard care. The control group will receive only routine nursing care without these additional comfort measures. Assessments will be made at baseline, 24 hours after admission, and 12 hours after completing the intervention. Participants and their parents will be involved in comfort, anxiety, fear, and sleep evaluations using various scales and wrist actigraphy to monitor sleep patterns. Parental state anxiety and satisfaction with care will also be assessed. The primary outcome is the childs behavioral comfort score measured at specified intervals. The study continues until 12 hours after the intervention, with all assessments closely monitored to evaluate the impact of the comfort intervention compared to standard care.

Researchers are evaluating oxidative stress markers in patients with chronic apical periodontitis who undergo a single session root canal treatment using different root canal sealers. The study aims to understand if there is a change in oxidative stress markers measured from saliva after treatment and whether these changes differ between two types of root canal sealers bioceramic-based and epoxy resin-based. This investigation is important to compare how these sealers may impact the oxidative stress in patients with this dental condition. Participants will receive root canal treatment in one session using a VDW Gold Reciproc device and reciprocal files. Two groups are studied one group treated with bioceramic-based sealer and the other with epoxyamine resin-based sealer. Saliva samples will be collected twiceonce during the treatment session and again 30 days after treatment. Additionally, periapical films will be taken before treatment to determine PAI scores, which will be compared to oxidative stress markers. During the study, participants will provide saliva samples at specified times, and dental evaluations including PAI scoring will be performed. Researchers will biochemically measure oxidative stress markers from saliva and endodontium samples to assess changes over about three months. The study monitors patient health and excludes those with conditions or behaviors that could affect results. Participants are informed about procedures and will sign consent forms before starting.

This research aims to collect comprehensive information on infants treated for retinopathy of prematurity ROP across multiple European countries. It is an observational registry study designed to gather data on the natural history of severe ROP, including variations in the diseases clinical features and progression, as well as treatment and follow-up patterns. The study is open-ended and includes infants regardless of the treatment method used at participating centers. The study involves enrolling preterm infants who require treatment for ROP according to national guidelines. No additional examinations or interventions are performed beyond routine clinical care. Data collected include baseline characteristics, treatment details at initial therapy and any re-treatments, and the stage of ROP through follow-up. Long-term ophthalmic and neurological development will also be tracked for up to 18 years. Participants clinical routine data are collected and documented electronically, focusing on treatment timing, disease progression, and outcomes. The primary outcomes include baseline data from birth to treatment, treatment parameters, and ROP stage through follow-up, typically spanning from birth to about one year. Secondary outcomes assess long-term eye and neurological health. This registry does not involve active treatment assignment and continues collecting data from infants treated at participating centers.

Researchers are investigating how combining different regional pain relief techniques affects recovery after open-heart surgery using median sternotomy. This trial focuses on the pectointercostal fascial plane block PIFB, which targets nerves around the sternum to control pain. The study also compares two other blocksrectus sheath block RSB and retro-intercostal fascial plane block RIFBto see if RIFB works as well as RSB, offering more options for pain management in cardiac surgery patients. Participants will be assigned to one of three groups one receiving only the bilateral PIFB, another receiving PIFB plus bilateral RSB, and a third receiving PIFB plus bilateral RIFB. These blocks are performed using ultrasound guidance with local anesthetic injections at specific anatomical sites either after anesthesia induction or at surgery end. The study aims to assess if combining these blocks improves postoperative pain control and recovery quality. Throughout the study, participants recovery will be monitored using the Turkish version of the Quality of Recovery-15 scale at 24 hours post-extubation as the main outcome, with additional assessments at 48 hours and before discharge. Pain intensity will be measured at multiple time points using the Numerical Rating Scale. Researchers will also track opioid use, side effects, and any complications related to the nerve blocks during the hospital stay, which typically lasts 5 to 7 days.

This research aims to predict the development of postdural puncture headache PDPH in pregnant women undergoing elective cesarean delivery with spinal anesthesia. PDPH is a common complication caused by cerebrospinal fluid leakage after dural puncture, leading to symptoms like headache, neck stiffness, and photophobia. The study explores changes in the optic nerve sheath diameter ONSD and cerebral oxygen levels as potential early indicators for PDPH, which could improve recovery and care for mothers and newborns. Participants are monitored for changes in ONSD at several time points before spinal anesthesia, 10 minutes after, at the end of surgery, and 24 hours postoperatively. The study also evaluates cerebral oxygen saturation during surgery using near-infrared spectroscopy NIRS. Patients are grouped based on whether they develop PDPH within five days after surgery, with assessments conducted in hospital rooms or via daily phone follow-ups. During the study, participants undergo clinical evaluations to track headache development and cerebral oxygenation changes. Outcomes measured include perioperative ONSD changes, cerebral oxygenation during surgery, and the incidence of post-spinal hypotension. Monitoring occurs throughout the perioperative and immediate postoperative periods, with the total study participation lasting up to five days post-surgery to assess PDPH occurrence and related physiological changes.

Researchers are studying first-line treatment options for participants with non-small cell lung cancer NSCLC in this Phase 23, multisite, randomized, open-label trial. The study includes two substudies based on NSCLC histological subtypes, which have different chemotherapy standards. This design allows evaluation of pumitamig BNT327 combined with chemotherapy and other investigational agents in participants with advanced NSCLC who have not received prior systemic treatment. Participants are randomized to receive one of two dose levels of pumitamig plus chemotherapy during the Phase 2 part of each substudy. In Phase 3, an independent data monitoring committee and a blinded independent central review will oversee safety and tumor assessments. Treatments include pumitamig combined with carboplatin and either pemetrexed or paclitaxel, or pembrolizumab with the same chemotherapies as active comparators. All drugs are given by intravenous infusion. The study period for each participant may last up to 64 months. Throughout the study, participants undergo regular tumor assessments and safety monitoring, including evaluation of adverse events, response rates, progression-free survival, and quality of life using validated questionnaires. Data on dose adjustments and treatment discontinuations are collected. Follow-up continues up to five years to assess long-term outcomes and survival. Participants receive detailed evaluations to understand treatment effects and safety over time in this comprehensive lung cancer trial.

Researchers are evaluating the effects of sexual counseling on pregnant women between 16 and 20 weeks of gestation. The study focuses on sexual function, marital adjustment, sexual quality of life, and mental health issues such as depression, anxiety, and stress during pregnancy and postpartum. It addresses common challenges and misconceptions about sexuality during pregnancy and postpartum, aiming to improve couples relationships in a cultural context where sexual topics are often taboo. Participants will be randomly assigned to either a sexual health education group or a routine care group. The education group will receive two face-to-face group counseling sessions by week 22 of pregnancy. Data will be collected before the intervention, after week 37 before delivery, and again three months after delivery to assess the effects of counseling during pregnancy and postpartum. Women in the study will complete evaluations at multiple points including questionnaires on sexual function, mental health, marital adjustment, and sexual life quality. Researchers will monitor changes from mid-pregnancy through three months postpartum. The study includes follow-up assessments to observe lasting impacts on participants, with total involvement spanning from about 16 weeks gestation to three months after childbirth.

Researchers are conducting a prospective, multicenter observational study to assess the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer NSCLC who have PD-L1 tumor cell expression of 50% or higher and no targetable mutations. The goal is to understand how atezolizumab performs in routine clinical practice in Trkiye, focusing on survival, treatment response, and safety. The study involves patients receiving atezolizumab as their first-line treatment for advanced NSCLC, with no study-mandated interventions or procedures. Treatments and follow-ups are carried out according to local standards of care at each center. Data is collected from routine medical records, including imaging, laboratory results, performance status, treatment exposure, and safety monitoring, reflecting real-world treatment patterns. Participants will be observed prospectively, with data collected up to 24 months for key outcomes such as overall survival, progression-free survival, response rates, and adverse events. The study monitors clinical outcomes without altering patient care, aiming to capture real-life practice variations and safety trends over time. Approximately 150 patients are expected to be enrolled for sufficient precision in evaluating long-term outcomes.